Skip to main content
Top
Published in: Tumor Biology 11/2014

01-11-2014 | Research Article

Fenofibrate enhances radiosensitivity of esophageal squamous cell carcinoma by suppressing hypoxia-inducible factor-1α expression

Authors: Yangyang Ge, Jia Liu, Xi Yang, Hongcheng Zhu, Baixia Yang, Kuiling Zhao, Zhijun Wu, Guojian Cheng, Feng Wang, Feng Ni, Qin Ge, Yanguang Yang, Guomei Tai, Xinchen Sun, Jing Cai

Published in: Tumor Biology | Issue 11/2014

Login to get access

Abstract

Radiation therapy is widely used in esophageal squamous cell carcinoma (ESCC). Promoting radiation sensitivity is important. Recent studies have shown that fenofibrate can inhibit the growth of several cancer lines and hypoxia-inducible factor-1α (HIF-1α) expression in MCF-7 cells. However, few studies on the radiosensitive effect of fenofibrate on ESCCs under hypoxic condition have been conducted. In this study, we assessed the radiosensitive effects of fenofibrate on human ESCC cells. In vitro experiments showed the inhibition of cytotoxic effects after ionizing irradiation. We measured cell viability and clonogenic survival rate. Flow cytometry showed that fenofibrate pretreatment promoted apoptosis. The in vivo data also suggest that fenofibrate had radiosensitizing effects in ECA-109 cells xenografted into nude mice. Western blot and immunohistochemical analyses revealed that the HIF-1α and vascular endothelial growth factor (VEGF) protein content decreased by fenofibrate. Thus, the inhibition of HIF-1α and VEGF expression in ESCC cells contributed to the radiosensitive effect. These data suggest that fenofibrate may be a potential radiosensitive drug.
Literature
1.
go back to reference Lee H, Park HC, Lee JA, et al. The efficacy of high-dose 3-dimensional conformal radiation therapy in patients with small hepatocellular carcinoma not eligible for other local modalities[J]. Am J Clin Oncol. 2013;36:162–6.PubMedCrossRef Lee H, Park HC, Lee JA, et al. The efficacy of high-dose 3-dimensional conformal radiation therapy in patients with small hepatocellular carcinoma not eligible for other local modalities[J]. Am J Clin Oncol. 2013;36:162–6.PubMedCrossRef
2.
go back to reference Dewas S, Mirabel X, Kramar A, et al. Stereotactic body radiation therapy for liver primary and metastases: the Lille experience [J]. Cancer Radiother. 2012;16:58–69.PubMedCrossRef Dewas S, Mirabel X, Kramar A, et al. Stereotactic body radiation therapy for liver primary and metastases: the Lille experience [J]. Cancer Radiother. 2012;16:58–69.PubMedCrossRef
3.
go back to reference Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States[J]. Surg Oncol Clin NAm. 2002;11:235–56.CrossRef Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States[J]. Surg Oncol Clin NAm. 2002;11:235–56.CrossRef
4.
go back to reference Belozerov VE, Van Meir EG. Hypoxia inducible factor-1: a novel target for cancer therapy[J]. Anti-Cancer Drugs. 2005;16:901–9.PubMedCrossRef Belozerov VE, Van Meir EG. Hypoxia inducible factor-1: a novel target for cancer therapy[J]. Anti-Cancer Drugs. 2005;16:901–9.PubMedCrossRef
5.
go back to reference Yang Y, Sun M, Wang L, Jiao B. HIFs, angiogenesis, and cancer[J]. J Cell Biochem. 2013;114:967–74.PubMedCrossRef Yang Y, Sun M, Wang L, Jiao B. HIFs, angiogenesis, and cancer[J]. J Cell Biochem. 2013;114:967–74.PubMedCrossRef
6.
go back to reference Meijer TW, Kaanders JH, et al. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. J Clin Cancer Res: Off J Am Assoc Cancer Res. 2012;18:5585–94.CrossRef Meijer TW, Kaanders JH, et al. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. J Clin Cancer Res: Off J Am Assoc Cancer Res. 2012;18:5585–94.CrossRef
7.
go back to reference Tanaka T, Kohno H, et al. Ligands for peroxisome proliferator-activated receptors α andγinhibit chemically induced colitis and formation of aberrant crypt foci in rats[J]. Cancer Res. 2001;61:2424–8.PubMed Tanaka T, Kohno H, et al. Ligands for peroxisome proliferator-activated receptors α andγinhibit chemically induced colitis and formation of aberrant crypt foci in rats[J]. Cancer Res. 2001;61:2424–8.PubMed
8.
go back to reference Maggiora M, Bologna M, et al. An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines[J]. Int J Cancer. 2001;112:909–19.CrossRef Maggiora M, Bologna M, et al. An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines[J]. Int J Cancer. 2001;112:909–19.CrossRef
9.
go back to reference Saidi SA, Holland CM, Charnock-Jones DS, et al. In vitro and in vivo effects of the PPARα agonists fenofibrate and retinoic acid in endometrial cancer[J]. Mol Cancer. 2006;5:13.PubMedCentralPubMedCrossRef Saidi SA, Holland CM, Charnock-Jones DS, et al. In vitro and in vivo effects of the PPARα agonists fenofibrate and retinoic acid in endometrial cancer[J]. Mol Cancer. 2006;5:13.PubMedCentralPubMedCrossRef
10.
go back to reference Thuillier P, Anchiraico GJ, Nickel KP, et al. Activators of peroxisome proliferator-activated-α partially inhibit mouse skin tumor promotion [J]. Mol Carcinog. 2000;29:134–42.PubMedCrossRef Thuillier P, Anchiraico GJ, Nickel KP, et al. Activators of peroxisome proliferator-activated-α partially inhibit mouse skin tumor promotion [J]. Mol Carcinog. 2000;29:134–42.PubMedCrossRef
11.
go back to reference Zhou J, Zhang S, Xue J, et al. Activation of peroxisome proliferator-activated receptor α (PPARα) suppresses hypoxia-inducible factor-1α(HIF-1α) signaling in cancer cells [J]. J Biol Chem. 2012;12:35161–9.CrossRef Zhou J, Zhang S, Xue J, et al. Activation of peroxisome proliferator-activated receptor α (PPARα) suppresses hypoxia-inducible factor-1α(HIF-1α) signaling in cancer cells [J]. J Biol Chem. 2012;12:35161–9.CrossRef
13.
go back to reference Vamesu S. Angiogenesis and tumor histologic type in primary breast cancer patients: an analysis of 155 needle core biopsies[J]. Rom J Morphol Embryol. 2008;49:181–8.PubMed Vamesu S. Angiogenesis and tumor histologic type in primary breast cancer patients: an analysis of 155 needle core biopsies[J]. Rom J Morphol Embryol. 2008;49:181–8.PubMed
14.
go back to reference Vermeulen PB, van Golen KL, Dirix LY. Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer: a review of the current knowledge [J]. Cancer. 2010;116:2748–54.PubMedCrossRef Vermeulen PB, van Golen KL, Dirix LY. Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer: a review of the current knowledge [J]. Cancer. 2010;116:2748–54.PubMedCrossRef
15.
go back to reference Grabacka M, Placha W, Plonka PM, et al. Inhibition of melanoma metastases by fenofibrate[J]. Arch Dermatol Res. 2004;296:54–8.PubMedCrossRef Grabacka M, Placha W, Plonka PM, et al. Inhibition of melanoma metastases by fenofibrate[J]. Arch Dermatol Res. 2004;296:54–8.PubMedCrossRef
16.
go back to reference Grabacka M, Plonka PM, Urbanska K, et al. Peroxisome proliferator activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt[J]. Clin Cancer Res. 2006;12:3028–36.PubMedCrossRef Grabacka M, Plonka PM, Urbanska K, et al. Peroxisome proliferator activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt[J]. Clin Cancer Res. 2006;12:3028–36.PubMedCrossRef
17.
go back to reference Tanaka T, Kohno H, Yoshitani S, et al. Ligands for peroxisome proliferator-activated receptors α andγinhibit chemically induced colitis and formation of aberrant crypt foci in rats[J]. Cancer Res. 2001;61:2424–8.PubMed Tanaka T, Kohno H, Yoshitani S, et al. Ligands for peroxisome proliferator-activated receptors α andγinhibit chemically induced colitis and formation of aberrant crypt foci in rats[J]. Cancer Res. 2001;61:2424–8.PubMed
18.
go back to reference Maggiora M, Bologna M, Cerù MP, et al. An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines[J]. Int J Cancer. 2001;112:909–19.CrossRef Maggiora M, Bologna M, Cerù MP, et al. An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines[J]. Int J Cancer. 2001;112:909–19.CrossRef
19.
go back to reference Zhang J, Lu A, Beech D, et al. Suppression of breast cancer metastasis through the inhibition of VEGF-mediated tumor angiogenesis[J]. Cancer Ther. 2007;5:273–86.PubMedCentralPubMed Zhang J, Lu A, Beech D, et al. Suppression of breast cancer metastasis through the inhibition of VEGF-mediated tumor angiogenesis[J]. Cancer Ther. 2007;5:273–86.PubMedCentralPubMed
20.
go back to reference Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 [J]. Mol Cell Biol. 1996;16:4604–13.PubMedCentralPubMed Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 [J]. Mol Cell Biol. 1996;16:4604–13.PubMedCentralPubMed
21.
go back to reference Han JY, Oh SH, Morgillo F, et al. Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer [J]. J Natl Cancer Inst. 2005;97:1272–86.PubMedCrossRef Han JY, Oh SH, Morgillo F, et al. Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer [J]. J Natl Cancer Inst. 2005;97:1272–86.PubMedCrossRef
22.
go back to reference Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension [J]. Proc Natl Acad Sci U S A. 1995;92:5510–4.PubMedCentralPubMedCrossRef Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension [J]. Proc Natl Acad Sci U S A. 1995;92:5510–4.PubMedCentralPubMedCrossRef
Metadata
Title
Fenofibrate enhances radiosensitivity of esophageal squamous cell carcinoma by suppressing hypoxia-inducible factor-1α expression
Authors
Yangyang Ge
Jia Liu
Xi Yang
Hongcheng Zhu
Baixia Yang
Kuiling Zhao
Zhijun Wu
Guojian Cheng
Feng Wang
Feng Ni
Qin Ge
Yanguang Yang
Guomei Tai
Xinchen Sun
Jing Cai
Publication date
01-11-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 11/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2149-9

Other articles of this Issue 11/2014

Tumor Biology 11/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine